Numerous studies have demonstrated that the second-generation medicines alectinib, ceritinib, brigatinib, and ensatinib can be more effective than chemotherapy when first-generation ALK inhibitors failed to treat NSCLC patients [115,116,117,118]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.